Organokinler ve Biyokimyasal Etkileri

Ahmet İlhan; Umut Kökbaş

doi:10.17827/aktd.1378295

Derleme

Organokines and Their Biochemical Effects

Yıl 2024, , 71 - 75, 31.03.2024

Ahmet İlhan , Umut Kökbaş

https://doi.org/10.17827/aktd.1378295

Öz

Obesity, which arises as a result of metabolic disorders, is one of the biggest global health problems. Obesity has contributed to the increased prevalence of sarcopenia, type 2 diabetes, and cardiovascular disease through excessive energy intake, a sedentary lifestyle, and aging. New research on organokines may lead to the development of promising biomarkers and therapeutics for cardiometabolic diseases. Investigating the biochemical effects of organokines can reveal the factors that contribute to the onset and progression of metabolic diseases. In this review, the main organokines have been identified and their biochemical effects have been discussed.

Anahtar Kelimeler

Organokines, Biomarkers, Metabolism, Obesity

Kaynakça

1. Ji YL, Eunju K. The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and exercise. Metabolites. 2023;13(9):979.
2. Faramia J, Ostinelli G, Drolet-Labelle V, Picard F, Tchernof A. Metabolic adaptations after bariatric surgery: Adipokines, myokines and hepatokines. Curr. Opin. Pharmacol. 2020, 52, 67–74.
3. Bluher M. Clinical relevance of adipokines. Diabetes Metab J. 2012;36:317–327.
4. Choi KM. The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis. Endocrinol Metab. 2016;31(1):1-6.
5. Frithioff-Bøjsøe C, Lund MA, Lausten-Thomsen U, Hedley PL, Pedersen O, Christiansen M, Baker J Let all. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr. Diab. 2020, 21, 194–202.
6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
7. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011;301: E567-84.
8. Bluher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 2015;64:131-45.
9. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75.
10. Gonzalez-Gil AM, Elizondo-Montemayor L. The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: A review. Nutrients 2020, 12, 1899.
11. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013;2:133-41.
12. Oh KJ, Lee DS, Kim WK, Han BS, Lee SC, Bae KH. Metabolic adaptation in obesity and type II diabetes: Myokines, adipokines and hepatokines. Int. J. Mol. Sci. 2016, 18, 8.
13. Musovic S, Shrestha MM, Komai AM, Olofsson CS. Resistin is co-secreted with adiponectin in white mouse adipocytes. Biochem. Biophys. Res. Commun. 2020, 534, 707–713.
14. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C et al. Asprosin is a centrally acting orexigenic hormone. Nat. Med. 2017, 23, 1444.
15. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia, F et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 2016, 165, 566–579.
16. Shi J, Fan J, Su Q, Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front. Endocrinol. 2019, 10, 703.
17. Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose tissue-derived omentin-1 function and regulation. Compr. Physiol. 2017, 7, 765–781.
18. Cuevas-Ramos D, Mehta R, Aguilar-Salinas C.A. Fibroblast growth factor 21 and browning of white adipose tissue. Front. Physiol. 2019, 10, 37.
19. Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose tissue-derived omentin-1 function and regulation. Compr. Physiol. 2017, 7, 765–781.
20. Barbalho SM, Flato UAP, Tofano RJ, Goulart RA, Guiguer EL, Detregiachi, CRP et al. Physical exercise and myokines: Relationships with sarcopenia and cardiovascular complications. Int. J. Mol. Sci. 2020, 21, 3607.
21. Mikolasevic I, Pavic T, Kanizaj TF, Bender DV, Domislovic V, Krznaric Z. Nonalcoholic fatty liver disease and sarcopenia: Where do we stand? Can. J. Gastroenterol. Hepatol. 2020, 2020, 8859719.
22. Kwon JH, Moon KM, Min KW. Exercise-induced myokines can explain the importance of physical activity in the elderly: An overview. Healthcare 2020, 8, 378.
23. Chung HS, Choi, KM. Organokines in disease. Adv. Clin. Chem. 2020, 94, 261–321.
24. Choi KM. The impact of organokines on insulin resistance, inflammation, and atherosclerosis. Endocrinol. Metab. 2016, 31, 1–6.
25. Lőrincz H, Somodi S, Ratku B, Harangi M, Paragh, G. Crucial regulatory role of organokines in relation to metabolic changes in non-diabetic obesity. Metabolites. 2023 13(2), 270.
26. Ruth CM, Andrew JH, Morris A, Russell DB, Jennifer CYL, Burke M, et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab. 2015, 22, 1078–1089.
27. Meex RCR, Watt, M.J. Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017, 13, 509–520.
28. Hashimoto O, Funaba M, Sekiyama K, Doi S, Shindo D, Satoh et al. Activin E controls energy homeostasis in both brown and white adipose tissues as a hepatokine. Cell Rep. 2018, 25, 1193–1203.
29. Pohl R, Haberl EM, Rein-Fischboeck L, Zimny S, Neumann M, Aslanidis C, Schacherer et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur. J. Clin. Investig. 2017, 47, 7–18.
30. Misu H, Takayama H, Saito Y, Mita Y, Kikuchi A, Ishii KA et al. Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Nat. Med. 2017, 23, 508–516.